About Our AML Clinical Trial
The AML Clinical Trial is investigating the use of 131I apamistamab (Iomab-B) in patients age 55+ with active, relapsed or refractory Acute Myeloid Leukemia (AML), to enable bone marrow transplant (BMT).
Many AML patients today are not eligible for potentially curative bone marrow transplant because of their health status or they have active disease and are unable to get into remission with chemotherapy. The SIERRA clinical trial for Acute Myeloid Leukemia may be an option for you. The trial does not require a patient to be in remission to potentially get a bone marrow transplant.
Edward Agura, MD, Texas Oncology – Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase 3 SIERRA trial.
Study Design
Study Locations
The SIERRA clinical trial Phase 3 Trial is now enrolling and being conducted at 22 major cancer centers in the United States and Canada:
- Banner MD Anderson – Gilbert, AZ
- Yale Cancer Center – New Haven, CT
- Mayo Clinic – Jacksonville, FL
- Loyola University – Maywood, IL
- University Of Iowa – Iowa City, IA
- University of Kansas – Kansas City, KS
- Mayo Clinic – Rochester, MN
- Washington University – St. Louis, MO
- University of Nebraska – Omaha, NE
- Memorial Sloan Kettering – New York, NY
- Stony Brook University – Stony Brook, NY
- Roswell Park – Buffalo, NY
- Weill Cornell Medicine – New York, NY
- Lineberger Comprehensive Cancer Center – Chapel Hill, NC
- Ohio State University – Columbus, OH
- University Hospitals – Cleveland, OH
- The Ottawa Hospital – Ottawa, ON Canada
- Princess Margaret Cancer Centre – Toronto, ON Canada
- Baylor University – Dallas, TX
- MD Anderson Cancer Center – Houston, TX
- Fred Hutch – Seattle, WA
- Medical College of Wisconsin – Milwaukee, WI
- Oregon Health & Science University (OHSU) – Portland, OR
- MedStar Georgetown University Hospital – Georgetown, DC
Contact a SIERRA Clinical Trial Location
Download our SIERRA study summary to facilitate a discussion with your doctor about participating in the SIERRA AML clinical trial
